Glioblastoma multiforme – terapia com curcumina, Boswellia, melatonina e vitamina C intravenosa

THE CASE OF MICHAEL JOHN TRAILL DUFFY:

Michael, then 54 year old, first came to our clinic in August 2013. He appeared weak and his records showed that he had experienced double vision, dizziness, imbalance, headaches, memory loss and hand-eye coordination problems in the past months.

Michael was diagnosed with Glioblastoma multiforme in March of 2013. The tumor was about 4 cm wide. He had undergone chemotherapy and radiation treatments. While finishing up final rounds of Temozolomide (TMZ) treatment, he was on other medication to control side effects like seizures and inflammation.

OUR INITIAL COMPLEMENTARY BEGAN AUG. 8, 2013:

 Boswellia s. (frankinsense) formulation, 750 mg per day  Curcumin-bound to coconut oil, 4.8 grams per day  Melatonin, 6 mg at night  Neem formulation, 900 mg per day  Amla jam, 1 teaspoon three times a day  All sugar and high carbohydrates were eliminated from his diet o Michael transformed his diet to eat mostly vegetables, nuts, seeds, fish, other meats, etc. o He minimized exposure to unhealthy diet choices  Vitamin C IV , once every week: o 25 grams of Vitamin C was infused once per week o Michael sat in an sauna during the IV

In March of 2014, a follow-up MRI showed that the tumor had shrunk from 4 cm to 2.7 cm in size. This was wonderful, very encouraging news.

Michael also reported that, since starting the complementary regimen, he had no side effects of chemotherapy, numbness and tingling was gone, nausea had retreated, and his and mood had significantly improved. Blisters related to Avastin treatments, pruritis related to other medication, as well as constipation had improved.

Next, additional herbal support for his adrenal glands and nervous system was added:  Bacopa m. formulation contains herbs like Brahmi and Gotu Kola that support nerve tissue health and may promote regeneration  Ashwagandha for adrenal support, as well as anti- support  Melotonin, 20 mg at night  Continue Vitamin C IV therapy

We got to know Michael well while he received the Vitamin C IVs for 2 to 3 hours every week. We witnessed the courageous and stoic nature of this man who was facing certain death in his mid-50s. For the year and a half that Michael came to the clinic, he was always pleasant and endearing. Michael connected with everyone and won them over with his humor and gentle manner.

In September of 2014, while the cancer had stabilized, Michael took a cruise around the Mediterranean with his lovely wife Tracy. Michael and Tracy described it as, “the trip of a lifetime.” They had minimal to no difficulty continuing the supplements.

The following month, the MRI report had ominous news: the tumor had grown in size significantly.

Despite this, Michael was still doing fairly well. Symptoms of balance, numbness, tingling and forgetfulness were a bit worse, but not significantly debilitating. Michael still had energy to do many things, including cooking breakfast “his favorite meal of the day.”

After several weeks in deliberation, Michael decided to try Novocure electric field therapy and one more round of chemotherapy Avastin. Unfortunately, Michael was never physically the same after this. His energy, balance and coordination diminished rapidly over the course of a couple of months.

In early 2015, Michael was provided hospice services for care in his final days. He was also supported by his wife Tracy, sister, father and two daughters.

Despite failing physical health, Michael maintained his humor, love of reading and joy for the outdoors. Michael was still the loving, inspiring and courageous person he had always been.

Almost 20 years ago, I had another patient with stage 4 glioblastoma. He had a tumor the size of a grapefruit in the middle of two hemispheres. In 9 months of Ayurvedic treatment, the tumor shrank to the size of walnut and was removed surgically. The patient lost some motor functions, but he lived for more than 8 years.

As we mourn Michael’s loss, we continue our research quest to achieve more effective treatments and better health outcomes for all patients facing cancer. REFERENCES

 [1] Thakkar JP, et al. Epidemiologic and Molecular Prognostic Review of Glioblastoma. Epidemiol Biomarkers Prev; 23(10) October 2014.  [2] Schwartzbaum JA, et al. Epidemiology and Molecular Pathology of Glioma. Natural Clinical Practice, Neurology, Sept. 2009; Vol. 2(9), Pg. 494-501.  [3] Stupp R, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96.  [4] Williams BA. Treatment Options for Glioblastoma and other Gliomas. Glioblastoma Diagnosis; March 10, 2014.  [5] Plenary Session of ASCO 2013. RTOG0825: Phase III double-blind placebocontrolled trial evaluating bevacizumab (BEV) in patients with newly diagnosed glioblastoma (GBM). J. Clin. Oncol, 2013; Vol. 13.  [6] Rulseh AM, et al. Long-term survival of patients suffering from glioblastoma multiforme treated with tumor-treating fields. World J Surg Oncol. 2012 Oct 24; Vol. 10, Pg. 220.  [7] Stupp R, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012 Sep; Vol. 48(14): Pg. 2192-202.  [8] Mikirova N, et al. “Clinical experience with intravenous administration of ascorbic acid: achievable levels in blood for different states of inflammation and disease in cancer patients.” Journal of Translational Medicine, 2013: Vol. 11(191).  [9] Riordan NH, Riordan HRD, Meng X, Li Y, Jackson JA: Intravenous ascorbate as a tumor cytotoxic chemotherapeutic agent. Medical hypothesis 1995, 44:207–213.  [10] Ohno S, et al. High-dose Vitamin C (Ascorbic Acid) Therapy in the Treatment of Patients with Advanced Cancer. Anti-cancer Research, 2009; Vol. 29: 809-816.  [11] Bock PR, et al. “Targeting Inflammation in Cancer-Related-Fatigue: A Rationale for Mistletoe Therapy as Supportive Care in Colorectal Cancer Patients.” Inflammation & Allergy – Drug Targets, 2014, 13, 105-111.  [12] Kienle GS, Kiene H. “Complementary cancer therapy: a systematic review of prospective clinical trials on anthroposophic mistletoe extracts.” European Journal of Medical Research, 2007 Mar 26; Vol. 12(3), Pg. 103-19.  [13] S. Koduru, et al. “Notch-1 inhibition by Withaferin-A: A therapeutic target against colon carcinogenesis,” Mol Cancer Ther., Jan. 2010, Vol. 9(1), Pg. 202–210.  [14] S.D, Stan, et al., “Ayurvedic medicine constituent withaferin A causes G2 and M phase cell cycle arrest in human breast cancer cells,” Nutr Cancer., 2008; Vol 60 (Suppl 1), Pg. 51– 60.  [15] T. Jeyanthi and P. Subramanian, “Protective effect of Withania somnifera root powder on lipid peroxidation and anti-oxidant status in gentamicin-induced nephrotoxic rats,” J Basic Clin Physiol Pharmacol, 2010, Vol. 21(1), Pg. 61–78.  [16] Nina-Chainani, N. “Safety and Anti-Inflammatory Activity of Curcumin: A Component of Tumeric (Curcuma longa).” The Journal of Complementary and , 2003; Vol 9(1), pp. 161–168.  [17] Plummer SM, et al. “Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kB activation via the NIK/IKK signalling complex.” Oncogene (1999); Vol. 18, Pg. 6013 – 6020.  [18] Kawamori T, et al. “Chemopreventive Effect of Curcumin, a Naturally Occurring Anti- Inflammatory Agent, during the Promotion/Progression Stages of Colon Cancer.” Cancer Res, February 1, 1999; Vol. 59, Pg. 597.  [19] Chauhan DP. “Chemotherapeutic Potential of Curcumin for Colorectal Cancer” Current Pharmaceutical Design, Sept. 2002; Vol 8(19), pp. 1695-1706.  [20] Bar-Sela, G, et al. “Curcumin as an Anti-Cancer Agent: Review of the Gap Between Basic and Clinical Applications.” Current Medicinal Chemistry, 2010; Vol. 17.  [21] Liu E, et al. Curcumin induces G2/M cell cycle arrest in a p53-dependent manner and upregulates ING4 expression in human glioma. J Neurooncol (2007) 85:263–270.  [22] Dhandapani K, et al. Curcumin suppresses growth and chemoresistance of human glioblastoma cells via AP-1 and NFκB transcription factors. Journal of Neurochemistry, July 2007, Volume 102, Issue 2, pages 522–538.  [23] G.B. Singh, et al. “Boswellic Acids— A New Class of Anti-inflammatory Drugs with a Novel Mode of Action.” International Seminar on , Calcutta, India, November 7–9, 1992.  [24] G.B. Singh and C.K. Atal, “Pharmacology of an extract of Boswellia guggalex–Boswellia serrata, a new non-steroidal anti-inflammatory agent,” Agents and Actions, 1986, Vol. 18, Pg. 407.  [25] Yadav VR, et al. Boswellic acid inhibits growth and metastasis of human colorectal cancer in orthotopic mouse model by downregulating inflammatory, proliferative, invasive and angiogenic biomarkers. Int J Cancer. 2012 May 1; Vol. 130(9), Pg. 2176-84.  [26] M. Lu, L. Xia, H. Hua, and Y. Jing, “Acetyl-keto-betaboswellic acid induces apoptosis through a death receptor 5-mediated pathway in prostate cancer cells,” Cancer Res., Feb 15, 2008, 68(4):1180–1186.  [27] Suhail MM, et al. “Boswellia sacra essential oil induces tumor cell-specific apoptosis and suppresses tumor aggressiveness in cultured human breast cancer cells” BMC Complementary and Alternative Medicine 2011; Vol. 11, Pg. 129.  [28] S. Kirste, et al. “Boswellia serrata acts on cerebral edema in patients irradiated for brain tumors: a prospective, randomized, placebo-controlled, double-blind pilot trial,” Cancer, Aug. 15, 2011, 117(16):3788–3795.  [29] A.B. Kunnumakkara, et al. “Boswellic acid blocks signal transducers and activators of transcription 3 signaling, proliferation, and survival of multiple myeloma via the protein tyrosine phosphatase SHP-1,” Mol Cancer Res., Jan. 2009, 7(1):118–128.  [30] Flavin DF. “A lipoxygenase inhibitor in breast cancer brain metastasis.” J Neurooncol. 2007; Vol. 82, Pg. 91-93  [31] Frawley D. and The Mind: The Healing of Consciousness. 1st edition, Lotus Press, Twin Lakes, WI, 1997.  [32] Lad V. Ayurveda: The Science of Self-Healing. 2nd edition, Lotus press, Twin Lakes, WI, 1985.  [33] Bertout JA, et al. The impact of O2 availability on human cancer. Nat Rev Cancer. 2008 December; Vol. 8(12): 967–975.  [34] Fayles AW, et al. Oxygenation predicts radiation response and survival in patients with cervix cancer.  [35] Dong XL, et al. Hypoxia decreased chemosensitivity of breast cancer cell line MCF-7 to paclitaxel through cyclin B1. Biomed Pharmacother. 2012 Feb; Vol. 66(1): Pg. 70-5.  [36] Moen I and Stuhr LE. Hyperbaric oxygen therapy and cancer–a review. Target Oncol. 2012 Dec; Vol. 7(4): Pg. 233-42.  [37] Chang HT, et al. Ketolytic and glycolytic enzymatic expression profiles in malignant gliomas: implication for ketogenic diet therapy. Nutr Metab (Lond). 2013 Jul 5; Vol. 10(1): Pg. 47.  [38] Woolf EC and Scheck AC. The ketogenic diet for the treatment of malignant glioma. J Lipid Res. 2015 Jan;56(1):5-10.  [39] Segerstrom S and Miller GE. Psychological Stress and the Human Immune System: A Meta-Analytic Study of 30 Years of Inquiry. Psychol Bull. 2004 July; Vol. 130(4), Pg. 601– 630  [40] Glaser R and Kiecolt-Glaser JK. “Stress-induced immune dysfunction: implications for health.” Nature Review, March 2005; Vol. 5, Pg. 243-251.  [41] Zamfir-Chiru AA, et al. “Melatonin and cancer” J Med Life. Sep 15, 2014; Vol. 7(3): Pg. 373–374.  [42] Kang DH, et al. “Dose effects of relaxation practice on immune responses in women newly diagnosed with breast cancer: an exploratory study.” Oncol Nurs Forum. 2011 May; Vol. 38(3), Pg. E240-52.  [43] Phuong LK, et al. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. Cancer Res. 2003;63(10):2462–2469.  [44] Galanis E, et al. Phase I trial of intraperitoneal (IP) administration of a measles virus (MV) derivative expressing the human carcinoembryonic antigen (CEA) in recurrent ovarian cancer (OvCa) J Clin Oncol. 2008;26(15S) Abs 5538.  [45] Mitchell DA, et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature; Vol. 519, 366–369.  [46] Gromeier M, Lachmann S, Rosenfeld MR, et al: Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc Natl Acad Sci, 2000; Vol 97, Pg. 6803-6808.  [47] Cannabis and Cannbinoids.  [48] Massi and Parolaro. Cannabinoids as a Potential New Therapy for Gliomas. Expert Review Neurotherapeutics, 2008; Vol. 8(1)  [49] Massi P, et al. Antitumor Effects of Cannabidiol, a Nonpsychoactive Cannabinoid, on Human Glioma Cell Lines. JPET March 2004; vol. 308(3), Pg. 838-845.  [50] Vaccani A, et al. Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. BJP, 2005; Vol. 144(8).  [51] Torres S, et al. A Combined Preclinical Therapy of Cannabinoids and Temozolomide against Glioma. Mol Cancer Ther January 2011; Vol. 10, Pg. 90.